—
C+
C+ The full Closelook — membership. Open the C+ overview

argenx NV ADR (ARGX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — argenx NV ADR

ARGX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie. The company is based in Amsterdam and lists as an ADR in the United States.
Where it sits in the stack
argenx sits outside our AI build-out index; it belongs to the Healthcare sector of Closelook's universe, grouped with commercial-stage biopharma names rather than any stack layer.
Who it is priced against
Closelook's peer group places it with other scored US healthcare names, chosen for sharing sector and country rather than therapy area, including Regeneron, Vertex, BeiGene and Medpace; the market also names Alexion as a comparator in rare-disease antibody treatment.
Why Closelook tracks it
argenx carries a Closelook score built from three scored modules so far, with momentum reading strongest and valuation reading weakest. It holds no seat in our indices and has appeared once in the diary, in a Midday 10 note listing it among large-cap healthcare names hitting new highs.
What the diary watches
The diary watches whether further scored modules shift the balance between its strong momentum reading and its weaker valuation one as commercial data on VYVGART and pipeline readouts accumulate.

argenx NV ADR (ARGX) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 64/100 composite (momentum 79, quality 74, valuation 27) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ARGX, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 8 analyst actions on the wire · latest: price target by Morgan Stanley, 2026-08-31

The Street on this name

Analyst actions and the latest print for ARGX from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Morgan Stanley — target 1,250 from 1,230 Target raised to $1250 from $1230 (+22.2% to spot) 2026-08-31
  • Price target Wells Fargo — target 1,415 from 1,350 Target raised to $1415 from $1350 (+38.8% to spot) 2026-08-26
  • Downgrade Deutsche Bank — Buy → Hold Downgraded to Hold from Buy 2026-08-24

8 actions on the analyst wire since 2026-08-13: 1 downgrade, 7 target changes. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against ARGX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What ARGX pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +1.3% in FY2025 248 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sector × region Health care in US: +1.8% week · −4.1% month · +13.2% quarter · +8.1% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-20
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is argenx NV ADR (ARGX)?

argenx NV ADR trades as ARGX on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-19.

Is ARGX in a Closelook index?

Not currently — argenx NV ADR is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

What is argenx NV ADR's Closelook composite score?

64 out of 100, with momentum 79, quality 74 and valuation 27 sub-scores, as of 2026-09-19. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ARGX trade against its moving averages?

Uptrend stack intact: Trades +5.5% vs the 50-day and +16.8% vs the 200-day average, 7.7% below the 52-week high and +49.6% off the 52-week low; a golden cross printed 70 sessions ago. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does argenx NV ADR do?

argenx develops antibody-based therapies for autoimmune disease and sells VYVGART for a rare neuromuscular disorder called generalised myasthenia gravis, plus a related formulation for immune thrombocytopenia and inflammatory nerve disease. Its pipeline includes further FcRn-targeted antibodies and candidates aimed at inflammation, IgA and other immune pathways, developed alone or through partners such as Zai Lab, Halozyme, OncoVerity and AbbVie. The company is based in Amsterdam and lists as an ADR in the United States. Closelook's peer group places it with other scored US healthcare names, chosen for sharing sector and country rather than therapy area, including Regeneron, Vertex, BeiGene and Medpace; the market also names Alexion as a comparator in rare-disease antibody treatment.

Where does argenx NV ADR sit in the AI build-out?

argenx sits outside our AI build-out index; it belongs to the Healthcare sector of Closelook's universe, grouped with commercial-stage biopharma names rather than any stack layer. argenx carries a Closelook score built from three scored modules so far, with momentum reading strongest and valuation reading weakest. It holds no seat in our indices and has appeared once in the diary, in a Midday 10 note listing it among large-cap healthcare names hitting new highs.

Does argenx NV ADR pay a dividend?

No cash distribution shows in argenx NV ADR’s price series over the last three years. The share count rose 1.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on argenx NV ADR recently?

The most recent analyst action on argenx NV ADR on the Closelook wire is a price target by Morgan Stanley on 2026-08-31 (target 1,250 from 1,230). 8 actions on the analyst wire since 2026-08-13: 1 downgrade, 7 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

Where has Closelook written about argenx NV ADR?

argenx NV ADR appears in 1 Closelook piece, most recently Midday 10: A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000 (2026-08-21). What Closelook said most recently: Barchart's large-cap 52-week new-high list, as of 11:59 CDT, carries 31 names and reads like the ex-tech thesis printed as breadth: twelve are health care, biotech or pharma — ARGX, BDX, BIO, CORT, HALO, MRK, REGN, RVTY, THC, TVTX, TXG… (Midday 10, 2026-08-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for ARGX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 1 piece · newest: Midday 10, “A chart pick published at 95.10 this morning trades 107.92 by midday — Robinhood's triangle breaks up through the 100 shelf — as the CAC snaps seven straight red sessions and Bitcoin adds another six percent above 77,000” (2026-08-21)

Mentioned on Closelook

Where ARGX appears in the diary — 1 piece, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.